Medical aspects of biologic toxins

Anesthesiology Clinics of North America

Volumn 22, Issue 3, 2004, Pages 509-532

  Marks, James D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITOXIN; BACTERIAL TOXIN; BOTULINUM TOXIN; RECOMBINANT VACCINE; RICIN; STAPHYLOCOCCUS ENTEROTOXIN B;

AMINO ACID SEQUENCE; ANAMNESIS; BOTULISM; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DNA HYBRIDIZATION; ENZYME ACTIVE SITE; GENE AMPLIFICATION; HUMAN; IMMUNOASSAY; LABORATORY TEST; LUNG FUNCTION TEST; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PROTEIN STRUCTURE; REVIEW; SEROLOGY;

BACTERIAL TOXINS; BIOTERRORISM; BOTULINUM TOXINS; BOTULISM; DIAGNOSIS, DIFFERENTIAL; ENTEROTOXINS; HUMANS; RICIN;

EID: 4344715045     PISSN: 08898537     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atc.2004.05.010     Document Type: Review

References (136)

1. Centers for Disease Control and Prevention Botulism in the United States, 1899-1998. Handbook for epidemiologists, clinicians, and laboratory workers. 1998;US Department of Health and Human Services, Public Health Service, Atlanta (GA). Available at: http://www.bt.cdc.gov/agent/botulism/index.asp
2. Gill M.D. Bacterial toxins: a table of lethal amounts. Microbiol Rev. 46:1982;86-94
3. Herrero B.A., Ecklung A.E., Streett C.S., Ford D.F., King J.K. Experimental botulism in monkeys-a clinical pathological study. Exp Mol Pathol. 6(1):1967;84-95
4. Franz D.R., Pitt L.M., Clayton M.A., Hanes M.A., Rose K.J. Efficacy of prophylactic and therapeutic administration of antitoxin for inhalation botulism. DasGupta B.R. Botulinum and tetanus neurotoxins: neurotransmission and biomedical aspects. 1993;473-476 Plenum Press, New York
5. Schantz E.J., Johnson E.A. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev. 56(1):1992;80-99
6. Scott A.B., Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord. 3(4):1988;333-335
7. Arnon S.A., Schecter R., Inglesby T.V., Henderson D.A., Bartlett J.G., Ascher M.S., et al. Botulinum toxin as a biological weapon. JAMA. 285:2001;1059-1070
8. Mahant N., Clouston P.D., Lorentz I.T. The current use of botulinum toxin. J Clin Neurosci. 7:2000;389-394
9. Sugiyama H. Clostridium botulinum neurotoxin. Microbiol Rev. 44(3):1980;419-448
10. Lacy D.B., Stevens R.C. Sequence homology and structural analysis of the Clostridial neurotxins. J Mol Biol. 291:1999;1091-1104
11. Middlebrook J.L., Franz D.R. Botulinum toxins. Sidell F.R., Takafuji E.T., Franz D.R. Medical aspects of chemical and biological warfare. 1997;643-654 Office of the Surgeon General, Washington, DC
12. Park J.B., Simpson L.L. Inhalational poisoning by botulinum toxin and inhalation vaccination with its heavy-chain component. Infect Immun. 71(3):2003;1147-1154
13. Meyer K.F. The rise and fall of botulism. Calif Med. 118:1973;63-64
14. Midura T.F., Arnon S.S. Infant botulism. Identification of Clostridium botulinum and its toxins in faeces. Lancet. 2(7992):1976;934-936
15. Pickett J., Berg B., Chaplin E., Brunstetter-Shafer M.A. Syndrome of botulism in infancy: clinical and electrophysiologic study. N Engl J Med. 295(14):1976;770-772
16. Davis J.B., Mattman L.H., Wiley M. Clostridium botulinum in a fatal wound infection. JAMA. 146:1951;934-936
17. Werner S.B., Passaro D., McGee J., Schechter R., Vugia D.J. Wound botulism in California, 1951-1998: recent epidemic in heroin injectors. Clin Infect Dis. 31(4):2000;1018-1024
18. Centers for Disease Control and Prevention Botulism-United States, 1978. MMWR Morb Mortal Wkly Rep. 28:1978;73-75
19. Chia J.K., Clark J.B., Ryan C.A., Pollack M. Botulism in an adult associated with food-borne intestinal infection with Clostridium botulinum. N Engl J Med. 315(4):1986;239-241
20. Griffin P.M., Hatheway C.L., Rosenbaum R.B., Sokolow R. Endogenous antibody production to botulinum toxin in an adult with intestinal colonization botulism and underlying Crohn's disease. J Infect Dis. 175(3):1997;633-637
21. Holzer E. Botulismus durch inhalation. Med Klin. 41:1962;1735-1740
22. Cobb D.B., Watson W.A., Fernandez M.C. Botulism-like syndrome after injection of botulinum toxin. Vet Hum Toxicol. 42:2000;163
23. United Nations Security Council Tenth report of the executive committee of the special commision established by the secretary-general pursuant to paragraph 9(b)(I) of security council resolution 687 (1991), and paragraph 3 of resolution 699 (1991) on the activities of the Special Commision. 1995;United Nations Security Council, New York
24. Bozheyeva G., Kunakbayev Y., Yeleukenov D. Former soviet biological weapons facilities in Kazakhstan: past, present, and future. 1999;Center for Nonproliferation Studies, Monterey Institute of International Studies, Monterey (CA)
25. Zilinskas R.A. Iraq's biological weapons: the past as future? JAMA. 278:1997;418-424
26. St. John R., Finlay B., Blair C. Bioterrorism in Canada: an economic assessment of prevention and postattack exposure. Can J Infect Dis. 12:2001;275-284
27. Hatheway C.L. Toxigenic clostridia. Clin Microbiol Rev. 3(1):1990;66-98
28. Hatheway C.L. Botulism: the present status of the disease. Curr Top Microbiol Immunol. 195:1995;55-75
29. Aureli P., Fenicia L., Pasolini B., Gianfranceschi M., McCroskey L.M., Hatheway C.L. Two cases of type E infant botulism caused by neurotoxigenic Clostridium butyricum in Italy. J Infect Dis. 154(2):1986;207-211
30. McCroskey L.M., Hatheway C.L., Fenicia L., Pasolini B., Aureli P. Characterization of an organism that produces type E botulinal toxin but which resembles Clostridium butyricum from the feces of an infant with type E botulism. J Clin Microbiol. 23(1):1986;201-202
31. Hall J.D., McCroskey L.M., Pincomb B.J., Hatheway C.L. Isolation of an organism resembling Clostridium barati which produces type F botulinal toxin from an infant with botulism. J Clin Microbiol. 21(4):1985;654-655
32. McCroskey L.M., Hatheway C.L., Woodruff B.A., Greenberg J.A., Jurgenson P. Type F botulism due to neurotoxigenic Clostridium baratii from an unknown source in an adult. J Clin Microbiol. 29(11):1991;2618-2620
33. Borland E.D., Moryson C.J., Smith G.R. Avian botulism and the high prevalence of Clostridium botulinum in the Norflok Broads. Vet Rec. 100(6):1977;106-109
34. Galvin J.W., Hollier T.J., Bodinnar K.D., Bunn C.M. An outbreak of botulism in wild waterbirds in southern Australia. J Wildl Dis. 21(4):1985;347-350
35. Jensen W.I., Price J.I. The global importance of type C botulism in wild birds. Eklund M.W. Avian botulism: an international perspective. 1987;33-54 Charles C. Thomas, Springfield (IL)
36. Smith G.R., Milligan R.A. Clostridium botulinum type D in Britain. Vet Rec. 100(6):1977;121-122
37. Demarchi J., Mourgues C., Orio J., Prevot A.R. Existence of botulism type C. Bull Acad Nat Med. 142:1958;580-582
38. Prevot A.R., Terrasse J., Daumail J., Cavaroc M., Riol J., Sillioc R. Existence in France of human botulism of type C. Bull Acad Med (Paris). 139:1955;355-358
39. Gimenez D.F., Ciccarelli A.S. Studies on strain 84 of Clostridium botulinum. Zentralbl Bakteriol. 215(2):1970;212-220
40. Gimenez D.F., Ciccarelli A.S. Clostridium botulinum in Argentina: present and future (Spanish). Rev Asoc Argent Microbiol. 8(2):1976;82-91
41. Sonnabend O., Sonnabend W., Heinzle R., Sigrist T., Dirnhofer R., Krech U. Isolation of Clostridium botulinum type G and identification of type G botulinal toxin in humans: report of five sudden unexpected deaths. J Infect Dis. 143(1):1981;22-27
42. Suen J.C., Hatheway C.L., Steigerwalt A.G., Brenner D.J. Clostridium argentinense, sp. nov: a genetically homogeneous group composed of all strains of Clostridium botulinum toxin type G and some nontoxigenic strains previously identified as clostridium subterminale or Clsotridium hastiforme. Int J Syst Bacteriol. 38:1988;375-381
43. Hatheway C.L., McCroskey L.M., Lombard G.L., Dowell V.R. Jr. Atypical toxin variant of Clostridium botulinum type B associated with infant botulism. J Clin Microbiol. 14(6):1981;607-611
44. Hatheway C.L., McCroskey L.M. Examination of feces and serum for diagnosis of infant botulism in 336 patients. J Clin Microbiol. 25(12):1987;2334-2338
45. Gimenez D.F. Clostridium botulinum Ba. Zentralbl Bakteriol Hyg. 257:1984;68-72
46. Santos-Buelga J.A., Collins M.D., East A.K. Characterization of the genes encoding the botulinum neurotoxin complex in a strain of Clostridium botulinum producing type B and F neurotoxins. Curr Microbiol. 37(5):1998;312-318
47. Dasgupta B.R., Boroff D.A., Rothstein E. Chromatographic fractionation of the crystalline toxin of Clostridium botulinum type A. Biochem Biophys Res Commun. 22(6):1966;750-756
48. DasGupta B.R., Boroff D.A. Separation of toxin and hemagglutinin from crystalline toxin of Clostridium botulinum type A by anion exchange chromatography and determination of their dimensions by gel filtration. J Biol Chem. 243(5):1968;1065-1072
49. Balding P., Gold E.R., Boroff D.A., Roberts T.A. Observations on receptor specific proteins. II. Haemagglutination and haemagglutination-inhibition reactions of Clostridium botulinum types A, C, D and E haemagglutinins. Immunology. 25(5):1973;773-782
50. East A.K., Stacey J.M., Collins M.D. Cloning and sequencing of a hemagglutinin component of the botulinum neurotoxin complex encoded by the Clostridium Botulinum types A and B. J Syst Bacteriol. 46:1994;1105-1112
51. Fujita R., Fujinaga Y., Inoue K., Nakajima H., Kumon H., Oguma K. Molecular characterization of two forms of nontoxic-nonhemagglutinin components of Clostridium botulinum type A progenitor toxins. FEBS Lett. 376(1-2):1995;41-44
52. East A.K., Bhandari M., Stacey J.M., Campbell K.D., Collins M.D. Organization phylogenetic interrelationships of genes encoding components of the botulinum toxin complex in proteolytic Clostridium botulinum types A, B, and F: evidence of chimeric sequences in the gene encoding the nontoxic nonhemagglutinin component. Int J Syst Bacteriol. 46(4):1996;1105-1112
53. Ohishi I., Sugii S., Sakaguchi G. Oral toxicities of Clostridium botulinum toxins in response to molecular size. Infect Immun. 16(1):1977;107-109
54. Chen F., Kuziemko G.M., Stevens R.C. Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex species. Infect Immun. 66(6):1998;2420-2425
55. Willems A., East A.K., Lawson P.A., Collins M.D. Sequence of the gene coding for the neurotoxin of Clostridium botulinum type A associated with infant botulism: comparison with other clostridial neurotoxins. Res Microbiol. 144(7):1993;547-556
56. Thompson D.E., Brehm J.K., Oultram J.D., Swinfield T.J., Shone C.C., Atkinson T., et al. The complete amino acid sequence of the Clostridium botulinum type A neurotoxin, deduced by nucleotide sequence analysis of the encoding gene. Eur J Biochem. 189(1):1990;73-81
57. Binz T., Kurazono H., Wille M., Frevert J., Wernars K., Niemann H. The complete sequence of botulinum neurotoxin type A and comparison with other clostridial neurotoxins. J Biol Chem. 265(16):1990;9153-9158
58. Whelan S.M., Elmore M.J., Bodsworth N.J., Brehm J.K., Atkinson T., Minton N.P. Molecular cloning of the Clostridium botulinum structural gene encoding the type B neurotoxin and determination of its entire nucleotide sequence. Appl Environ Microbiol. 58(8):1992;2345-2354
59. Ihara H., Kohda T., Morimoto F., Tsukamoto K., Karasawa T., Nakamura S., et al. Sequence of the gene for Clostridium botulinum type B neurotoxin associated with infant botulism, expression of the C-terminal half of heavy chain and its binding activity. Biochim Biophys Acta. 1625(1):2003;19-26
60. Hauser D., Eklund M.W., Kurazono H., Binz T., Niemann H., Gill D.M., et al. Nucleotide sequence of Clostridium botulinum C1 neurotoxin. Nucleic Acids Res. 18(16):1990;4924
61. Binz T., Kurazono H., Popoff M.R., Eklund M.W., Sakaguchi G., Kozaki S., et al. Nucleotide sequence of the gene encoding Clostridium botulinum neurotoxin type D. Nucleic Acids Res. 18(18):1990;5556
62. Whelan S.M., Elmore M.J., Bodsworth N.J., Atkinson T., Minton N.P. The complete amino acid sequence of the Clostridium botulinum type-E neurotoxin, derived by nucleotide-sequence analysis of the encoding gene. Eur J Biochem. 204(2):1992;657-667
63. Thompson D.E., Hutson R.A., East A.K., Allaway D., Collins M.D., Richardson P.T. Nucleotide sequence of the gene coding for Clostridium barati type F neurotoxin: comparison with other clostridial neurotoxins. FEMS Microbiol Lett. 108(2):1993;175-182
64. Campbell K., Collins M.D., East A.K. Nucleotide sequence of the gene coding for Clostridium botulinum (Clostridium argentinense) type G neurotoxin: genealogical comparison with other clostridial neurotoxins. Biochim Biophys Acta. 1216(3):1993;487-491
65. Gibson A.M., Modi N.K., Roberts T.A., Shone C.C., Hambleton P., Melling J. Evaluation of a monoclonal antibody-based immunoassay for detecting type A Clostridium botulinum toxin produced in pure culture and an inoculated model cured meat system. J Appl Bacteriol. 63(3):1987;217-226
66. Kozaki S., Kamata Y., Nishiki T., Kakinuma H., Maruyama H., Takahashi H., et al. Characterization of Clostridium botulinum type B neurotoxin associated with infant botulism in japan. Infect Immun. 66(10):1998;4811-4816
67. Lacy D.B., Tepp W., Cohen A.C., DasGupta B.R., Stevens R.C. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol. 5:1998;898-902
68. Hanson M.A., Stevens R.C. Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 A resolution. Nat Struct Biol. 7(8):2000;687-692
69. Eswaramoorthy S., Kumaran D., Swaminathan S. Crystallographic evidence for doxorubicin binding to the receptor-binding site in Clostridium botulinum neurotoxin B. Acta Crystallogr D Biol Crystallogr. 57(Pt 11):2001;1743-1746
70. Dolly J.O., Black J., Williams R.S., Melling J. Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization. Nature. 307:1984;457-460
71. Montecucco C. How do tetanus and botulinum toxins bind to neuronal membranes? Trends Biochem Sci. 11:1986;315-317
72. Simpson L.L. Kinetic studies on the interaction between botulinum toxin type A and the chloinergic neuromuscular junction. J Pharmacol Exp Ther. 212:1980;16-21
73. Nishiki T., Tokuyama Y., Kamata Y., Nemoto Y., Yoshida A., Sato K., et al. The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a. FEBS Lett. 378(3):1996;253-257
74. Schiavo G., Benfenati F.P.B., Rossetto O., Polverino de Laureto P., DasGupta B.R., Montecucco C. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature. 359:1992;832-835
75. Schiavo G., Rossetto O., Catsicas S., Polverino de Laureto P., DasGupta B.R., Benfenati F., et al. Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E. J Biol Chem. 268:1993;23784-23787
76. Schiavo G., Santucci A., Dasgupta B.R., Mehta P.P., Jontes J., Benfenati F., et al. Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds. FEBS Lett. 335(1):1993;99-103
77. Blasi J., Chapman E.R., Link E., Binz T., Yamasaki S., De Camilli P., et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature. 365(6442):1993;160-163
78. Binz T., Blasi J., Yamasaki S., Baumeister A., Link E., Sudhof T.C., et al. Proteolysis of SNAP-25 by types E and A botulinal neurotoxins. J Biol Chem. 269(3):1994;1617-1620
79. Schiavo G., Shone C.C., Rossetto O., Alexander F.C., Montecucco C. Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP/synaptobrevin. J Biol Chem. 268(16):1993;11516-11519
80. Schiavo G., Malizio C., Trimble W.S., Polverino de Laureto P., Milan G., Sugiyama H., et al. Botulinum G neurotoxin cleaves VAMP/synaptobrevin at a single Ala-Ala peptide bond. J Biol Chem. 269(32):1994;20213-20216
81. Yamasaki S., Hu Y., Binz T., Kalkuhl A., Kurazono H., Tamura T., et al. Synaptobrevin/vesicle-associated membrane protein (VAMP) of Aplysia californica: structure and proteolysis by tetanus toxin and botulinal neurotoxins type D and F. Proc Natl Acad Sci U S A. 91(11):1994;4688-4692
82. Yamasaki S., Binz T., Hayashi T., Szabo E., Yamasaki N., Eklund M., et al. Botulinum neurotoxin type G proteolyses the Ala81-Ala82 bond of rat synaptobrevin 2. Biochem Biophys Res Commun. 200(2):1994;829-835
83. Blasi J., Chapman E.R., Yamasaki S., Binz T., Niemann H., Jahn R. Botulinum neurotoxin C1 blocks neurotransmitter release by means of cleaving HPC-1/syntaxin. EMBO J. 12(12):1993;4821-4828
84. Foran P., Lawrence G.W., Shone C.C., Foster K.A., Dolly J.O. Botulinum neurotoxin C1 cleaves both syntaxin and SNAP-25 in intact and permeabilized chromaffin cells: correlation with its blockade of catecholamine release. Biochemistry. 35(8):1996;2630-2636
85. Sutton R.B., Fasshauer D., Jahn R., Brunger A.T. Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 A resolution. Nature. 395(6700):1998;347-353
86. Merson M.H., Dowell V.R. Jr. Epidemiologic, clinical and laboratory aspects of wound botulism. N Engl J Med. 289(19):1973;1105-1110
87. Wilson R., Morris J.G. Jr., Snyder J.D., Feldman R.A. Clinical characteristics of infant botulism in the United States: a study of the non-California cases. Pediatr Infect Dis. 1(3):1982;148-150
88. Hughes J.M., Blumenthal J.R., Merson M.H., Lombard G.L., Dowell V.R. Jr., Gangarosa E.J. Clinical features of types A and B food-borne botulism. Ann Intern Med. 95(4):1981;442-445
89. Woodruff B.A., Griffin P.M., McCroskey L.M., Smart J.F., Wainwright R.B., Bryant R.G., et al. Clinical and laboratory comparison of botulism from toxin types A, B, and E in the United States, 1975-1988. J Infect Dis. 166(6):1992;1281-1286
90. Amersdorfer P., Marks J.D. Phage libraries for generation of anti-botulinum scFv antibodies. Methods Mol Biol. 145:2000;219-240
91. Maroon J.C. Late effects of botulinum intoxication. JAMA. 238(2):1977;129
92. Mann J.M., Martin S., Hoffman R., Marrazzo S. Patient recovery from type A botulism: morbidity assessment following a large outbreak. Am J Public Health. 71(3):1981;266-269
93. Ehrenreich H., Garner C.G., Witt T.N. Complete bilateral internal ophthalmoplegia as sole clinical sign of botulism: confirmation of diagnosis by single fibre electromyography. J Neurol. 236(4):1989;243-245
94. Arnon S.S. Clinical trial of human botulism immune globulin. DasGupta B.R. Botulinum and tetanus neurotoxins: neurotransmission and biomedical aspects. 1993;477-482 Plenum Press, New York
95. de Paiva A., Meunier F.A., Molgo J., Aoki K.R., Dolly J.O. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A. 96(6):1999;3200-3205
96. Foran P.G., Mohammed N., Lisk G.O., Nagwaney S., Lawrence G.W., Johnson E., et al. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem. 278(2):2003;1363-1371
97. St Louis M.E., Peck S.H., Bowering D., Morgan G.B., Blatherwick J., Banerjee S., et al. Botulism from chopped garlic: delayed recognition of a major outbreak. Ann Intern Med. 108(3):1988;363-368
98. Blake P.A., Horwitz M.A., Hopkins L., Lombard G.L., McCroan J.E., Prucha J.C., et al. Type A botulism from commercially canned beef stew. South Med J. 70(1):1977;5-7
99. O'Mahony M., Mitchell E., Gilbert R.J., Hutchinson D.N., Begg N.T., Rodhouse J.C., et al. An outbreak of foodborne botulism associated with contaminated hazelnut yoghurt. Epidemiol Infect. 104(3):1990;389-395
100. Seals J.E., Snyder J.D., Edell T.A., Hatheway C.L., Johnson C.J., Swanson R.C., et al. Restaurant-associated type A botulism: transmission by potato salad. Am J Epidemiol. 113(4):1981;436-444
101. Dodds K.L. Restaurant-associated botulism outbreaks in North America. Food Contr. 1:1990;139-141
102. Eisenberg M.S., Bender T.R. Botulism in Alaska, 1947 through 1974. Early detection of cases and investigation of outbreaks as a means of reducing mortality. JAMA. 235(1):1976;35-38
103. Meyer K.F., Dubovsky B.J. The distribution of the spores of C. botulinum in the United States. J Infect Dis. 31:1922;559-594
104. Smith L.D.S. The occurence of Clostridium botulinum and Clostridium Tetani in the soil of the United States. Health Lab Sci. 15:1978;74-80
105. Bott T.L., Deffner J.S., McCoy E., Foster E.M. Clostridium botulinum type E in fish from the Great Lakes. J Bacteriol. 91(3):1966;919-924
106. Ward B.Q., Carroll B.J., Garrett E.S., Reese G.B. Survey of the US Gulf Coast for the presence of Clostridium botulinum. Appl Microbiol. 15(3):1967;629-636
107. Cherington M., Ginsberg S. Type B botulism: neurophysiologic studies. Neurology. 21(1):1971;43-46
108. Cherington M. Botulism. Ten-year experience. Arch Neurol. 30(6):1974;432-437
109. Cherington M. Clinical spectrum of botulism. Muscle Nerve. 21(6):1998;701-710
110. Maselli R.A., Bakshi N. AAEM case report 16. Botulism. American Association of Electrodiagnostic Medicine. Muscle Nerve. 23(7):2000;1137-1144
111. Dowell V.R. Jr., McCroskey L.M., Hatheway C.L., Lombard G.L., Hughes J.M., Merson M.H. Coproexamination for botulinal toxin and clostridium botulinum. A new procedure for laboratory diagnosis of botulism. JAMA. 238(17):1977;1829-1832
112. Emanuel P.A., Dang J., Gebhardt J.S., Aldrich J., Garber E.A., Kulaga H., et al. Recombinant antibodies: a new reagent for biological agent detection. Biosens Bioelectron. 14(10-11):2000;751-759
113. Peruski A.H., Johnson L.H. 3rd, Peruski L.F. Jr. Rapid and sensitive detection of biological warfare agents using time-resolved fluorescence assays. J Immunol Methods. 263(1-2):2002;35-41
114. Ferreira J.L., Eliasberg S.J., Harrison M.A., Edmonds P. Detection of preformed type A botulinal toxin in hash brown potatoes by using the mouse bioasssay and a modified ELISA test. J AOAC Int. 84(5):2001;1460-1464
115. Terranova W., Breman J.G., Locey R.P., Speck S. Botulism type B: epidemiologic aspects of an extensive outbreak. Am J Epidemiol. 108(2):1978;150-156
116. Tacket C.O., Shandera W.X., Mann J.M., Hargrett N.T., Blake P.A. Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am J Med. 76(5):1984;794-798
117. Schmidt-Nowara W.W., Samet J.M., Rosario P.A. Early and late pulmonary complications of botulism. Arch Intern Med. 143(3):1983;451-456
118. Hughes J.M., Tacket C.O. "Sausage poisoning" revisited. Arch Intern Med. 143(3):1983;425-427
119. Hibbs R.G., Weber J.T., Corwin A., Allos B.M., Abd el Rehim M.S., Sharkawy S.E., et al. Experience with the use of an investigational F(ab′)2 heptavalent botulism immune globulin of equine origin during an outbreak of type E origin in Egypt. Clin Infect Dis. 23:1996;337-340
120. Amersdorfer P., Wong C., Chen S., Smith T., Desphande S., Sheridan R., et al. Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed using phage antibody libraries. Infect Immun. 65:1997;3743-3752
121. Amersdorfer P., Wong C., Smith T., Chen S., Deshpande S., Sheridan R., et al. Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries. Vaccine. 20(11-12):2002;1640- 1648
122. Nowakowski A., Wang C., Powers D.B., Amersdorfer P., Smith T.J., Montgomery V.A., et al. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A. 99(17):2002;11346- 11350
123. Black R.E., Gunn R.A. Hypersensitivity reactions associated with botulinal antitoxin. Am J Med. 69:1980;567-570
124. Arnon S.S. Infant botulism. Feigen R., Cherry J. Textbook of pediatric infectious diseases. 1992;1095-1102 WB Saunders, Philadelphia
125. Siegel L.S. Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay. J Clin Microbiol. 26:1988;2351-2356
126. Byrne M.P., Smith L.A. Development of vaccines for prevention of botulism. Biochimie. 82:2000;955-966
127. Rosenbloom M., Leikin J.B., Vogel S.N., Chaudry Z.A. Biological and chemical agents: a brief synopsis. Am J Ther. 9:2002;5-14
128. Knight B. Ricin-a potent homicidal poison. BMJ. 1:1979;350-351
129. Mayor S. UK doctors warned after ricin poison found in police raid. BMJ. 326:2003;126
130. Centers for Disease Control and Prevention Investigation of a ricin-containing envelope at a postal facility - South Carolina, 2003. MMWR Morb Mortal Wkly Rep. 52:2003;1129-1131
131. Olsnes S., Kozlov J.V. Ricin. Toxicon. 39:2001;1723-1728
132. Rutenber E., Robertus J.D. Structure of ricin B-chain at 2.5 A resolution. Proteins. 10:1991;260-269
133. Endo Y., Mitsui K., Motizuki M., Tsurugi K. The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. The site and the characteristics of the modification in 28 S ribosomal RNA caused by the toxins. J Biol Chem. 262:1987;5908-5912
134. Endo Y., Tsurugi K. RNA N-glycosidase activity of ricin A-chain. Mechanism of action of the toxic lectin ricin in eukaryotic ribosomes. J Biol Chem. 262:1987;8128-8130
135. Greenfield R.A., Brown B.R., Hutchins J.B., Iandolo J.J., Jackson R., Slater L.N., et al. Microbiological, biological, and chemical weapons of warfare and terrorism. Am J Med Sci. 323(6):2002;326-340
136. Dyer D.W., Iandolo J.J. The staphylococcal enterotoxins-a genetic overview. J Food Safety. 3:1982;249-264